Ottawa invests in research to help Ontario ginseng growers improve yields

Sep 12, 2014

The federal government announced an investment of $423,000 to the Ontario Ginseng Growers Association (OGGA) aimed at helping the province’s 140 growers increase productivity and improve yields. Agriculture Minister Gerry Ritz and the Honourable Diane Finley, Member of Parliament for Haldimand-Norfolk made the announcement on Sept. 10 at a stop in Simcoe, Ont.

More specifically, the funds will seek to address one of the biggest problems facing the ginseng industry – managing ginseng replant disease. The disease is highly problematic for farmers because it creates a situation where by a healthy crop of ginseng is no longer possible to be grown on the same parcel of land where it had previously been produced.

“The ginseng industry is an important contributor to the economy in Ontario and across Canada. This investment in research will drive growth and productivity, ensuring a bright future for our ginseng producers and the industry overall,” Minister Ritz said in a release.

The investment directed to the OGGA will allow the industry group to examine the factors that lead to the disease and study potential solutions to this phenomenon. On the research side of things, the focus will be on the evaluation of fungicides, the introduction of beneficial organisms and a comparison of replant and non-replant sites.

The initiative will go hand in hand with work that is already underway. Agriculture Canada’s Pesticide Risk Reduction Program is conducting research focusing on understanding the factors which contribute to the disease, and looking at crop management practices. The investment was made possible thanks to the Agri-Food Canada’s AgriInnovation Program under Growing Forward 2.

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.